THIS TRIAL IS CLOSED. The trial suspended enrollment on August 21, 2023.

‍

The study is exploring the use of MRI-guided radiation therapy to deliver short-course radiation over 5 to 8 treatment days. The therapy involves delivering x-rays to the lung cancer while monitoring organ motion in real-time to avoid injury. The trial aims to determine the safety and effectiveness of this treatment and will monitor patients for side effects and tumor shrinkage or disappearance. This trial is for early-stage lung cancer patients who are unable to undergo surgery due to other medical conditions.

‍

Patients can participate if they are/have:

• Age ≥ 18 years of age
• Clinical diagnosis of NSCLC
• Stage T1-2b (≤ 5 cm)